This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Veeva's Vault eTMF Gets Implemented by Biotest for Trials
by Zacks Equity Research
Veeva's (VEEV) Vault eTMF should enable Biotest to manage all study documents and activities in real time.
The Zacks Analyst Blog Highlights: MDRX, VEEV, DGX, TMO and ZM
by Zacks Equity Research
The Zacks Analyst Blog Highlights: MDRX, VEEV, DGX, TMO and ZM
Is Another Great Depression Imminent or Is it Just a Myth?
by Urmimala Biswas
Asian countries have already shown clear signs of major economic recession.
Veeva Vault Picked by AstraZeneca for Quality Management
by Zacks Equity Research
The partnership with AstraZeneca will facilitate end-to-end quality management for Veeva (VEEVA).
The Zacks Analyst Blog Highlights: 10x Genomics, Allscripts Healthcare and NextGen Healthcare
by Zacks Equity Research
The Zacks Analyst Blog Highlights: 10x Genomics, Allscripts Healthcare and NextGen Healthcare
Here's Why You Should Retain Allscripts (MDRX) Stock for Now
by Zacks Equity Research
Investor confidence is high on Allscripts (MDRX) stock, thanks to solid prospects.
3 Med Info Stocks to Improve Portfolio Health Amid Coronavirus Woes
by Urmimala Biswas
Postponement of elective surgeries leading to lower product bookings cloud Zacks-Medical Info Systems industry prospects. However, coronavirus-led demand for contactless services should aid the space. TXG, MDRX, NXGN should be the forerunners.
3 Remote Patient Monitoring Stocks in Focus Amid Coronavirus
by Sriparna Ghosal
In the wake of the pandemic, the remote patient monitoring space continues to thrive on a number of positive developments.
AllScripts (MDRX) Up 18.4% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
AllScripts (MDRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Allscripts Enhances Healthcare Innovation With Patent Program
by Zacks Equity Research
Allscripts (MDRX) continues to advance healthcare innovation by earning five new application patents.
Allscripts' Collaboration to Advance Healthcare Innovation
by Zacks Equity Research
Allscripts (MDRX) partners with Israel's Sheba Medical Center to help enhance healthcare innovation with smarter technology, thereby improving patient outcomes.
Allscripts (MDRX) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Allscripts (MDRX) witnessed decline in core Client Services and Software delivery unit revenues during Q2.
AllScripts Healthcare (MDRX) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
AllScripts (MDRX) delivered earnings and revenue surprises of 50.00% and 1.60%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
New Strong Sell Stocks for July 29th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today.
Analysts Estimate AllScripts Healthcare (MDRX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
AllScripts (MDRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Allscripts Extends Strategic Partnership With Microsoft
by Zacks Equity Research
Allscripts (MDRX) extends partnership with Microsoft that can help transform healthcare with smarter technology, thereby improving patient outcomes.
Here's Why You Should Retain Allscripts (MDRX) Stock for Now
by Zacks Equity Research
Allscripts (MDRX) continues to benefit from lucrative deals and strong prospects in Sunrise EHR. However, margin contraction remains a woe.
Remote Patient Monitoring Gains Prominence: 3 Stocks to Watch
by Trina Mukherjee
Let's keep a watch on three stocks that are committed toward enhancing and offering RPM to fight against coronavirus.
Allscripts' (MDRX) Veradigm Partners with PAN Foundation
by Zacks Equity Research
This partnership between Allscripts (MDRX) and PAN Foundation is expected to boost patient outcomes.
3 Digital HealthCare Stocks in the Spotlight Amid Coronavirus
by Sriparna Ghosal
In the face of the pandemic, the digital health management space continues to thrive on a number of positive developments.
Allscripts (MDRX) Looks Good: Stock Adds 9.1% in Session
by Zacks Equity Research
Allscripts (MDRX) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.
AllScripts (MDRX) Up 18% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
AllScripts (MDRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Allscripts Unit Inks Deal to Boost Veradigm AccelRx Platform
by Zacks Equity Research
This deal is expected to bolster Allscripts' (MDRX) Clinical and Financial Solutions segment.
Allscripts (MDRX) Q1 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Allscripts (MDRX) witnessed a decline in core Client Services and Software delivery unit revenues in Q1.
AllScripts Healthcare (MDRX) Q1 Earnings and Revenues Miss Estimates
by Zacks Equity Research
AllScripts (MDRX) delivered earnings and revenue surprises of -35.71% and -1.17%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?